22NW, LP holds a concentrated book of 16 stocks worth $145.9M as of Q1 2026 (disclosed May 15, 2026, a ~45-day 13F lag). This quarter they opened FOX FACTORY HOLDING CORP and trimmed FOSTER (LB) CO-A. Their largest long position is FOSTER (LB) CO-A at 20% of the equity book.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1694297/holdings"
Use Arkolith to show 22NW, LP's latest holdings, largest changes, and filing provenance.
Top-heavy: concentrated book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
30% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Foster L B Co COM | $29.8M | 1.07M | 20.4% | ▼−10% Reduced · −124K sh | |
| 2 | Nektar Therapeutics COM NEW | $20.2M | 281.1K | 13.9% | ▼−15% Reduced · −50K sh | |
| 3 | Lifecore Biomedical Inc COM | $18.9M | 1.3K | 12.9% | —Held | |
| 4 | Insperity Inc COM | $13.3M | 493.0K | 9.1% | ▲+412% Added · +397K sh | |
| 5 | Mineralys Therapeutics Inc COM | $12.0M | 444.3K | 8.2% | ▲+24% Added · +86K sh | |
| 6 | Stoneridge Inc COM | $11.9M | 2.47M | 8.2% | ▲+13% Added · +274K sh | |
| 7 | Fox Factory Hldg Corp COM | $11.2M | 678.2K | 7.7% | ▲New New position | |
| 8 | Culp Inc COM | $5.1M | 1.86M | 3.5% | —Held | |
| 9 | Core Molding Technologies In COM | $5.0M | 222.7K | 3.4% | —Held | |
| 10 | Regenxbio Inc COM | $4.1M | 492.8K | 2.8% | ▼−47% Reduced · −431K sh | |
| 11 | Unifi Inc COM NEW | $3.0M | 852.5K | 2.1% | —Held | |
| 12 | Team Inc COM NEW | $2.7M | 170.2K | 1.9% | —Held | |
| 13 | Rezolute Inc COM NEW | $2.5M | 820.7K | 1.7% | —Held | |
| 14 | Farmer Bros Co COM | $2.5M | 1.96M | 1.7% | —Held | |
| 15 | Eledon Pharmaceuticals Inc COM | $2.0M | 636.4K | 1.3% | —Held | |
| 16 | Phenixfin Corp COM | $1.7M | 43.1K | 1.2% | ▼−63% Reduced · −75K sh |
As-of date vs the date the SEC received each filing
| Quarter | As of | Filed | Positions | Value | Form |
|---|---|---|---|---|---|
| Q1 2026 | Mar 31, 2026 | May 15, 2026 | 16 | $145.9M | 13F-HR |
| Q4 2025 | Dec 31, 2025 | Feb 13, 2026 | 20 | $237.6M | 13F-HR |
| Q3 2025 | Sep 30, 2025 | Nov 14, 2025 | 21 | $212.3M | 13F-HR |
| Q2 2025 | Jun 30, 2025 | Aug 14, 2025 | 21 | $158.8M | 13F-HR |
| Q1 2025 | Mar 31, 2025 | May 14, 2025 | 20 | $149.1M | 13F-HR |
| Q4 2024 | Dec 31, 2024 | Feb 14, 2025 | 16 | $158.5M | 13F-HR |
| Q3 2024 | Sep 30, 2024 | Nov 14, 2024 | 13 | $119.3M | 13F-HR |
| Q2 2024 | Jun 30, 2024 | Aug 14, 2024 | 13 | $117.2M | 13F-HR |
| Q1 2024 | Mar 31, 2024 | May 15, 2024 | 13 | $116.1M | 13F-HR |
| Q4 2023 | Dec 31, 2023 | Feb 14, 2024 | 14 | $153.5M | 13F-HR |
| Q3 2023 | Sep 30, 2023 | Nov 14, 2023 | 14 | $140.3M | 13F-HR |
| Q2 2023 | Jun 30, 2023 | Aug 14, 2023 | 14 | $160.1M | 13F-HR |
| Q1 2023 | Mar 31, 2023 | May 15, 2023 | 17 | $162.7M | 13F-HR |
| Q4 2022 | Dec 31, 2022 | Feb 10, 2023 | 19 | $185.2M | 13F-HR |
| Q3 2022 | Sep 30, 2022 | Nov 14, 2022 | 20 | $176.8M | 13F-HR |
| Q2 2022 | Jun 30, 2022 | Aug 12, 2022 | 20 | $188.4M | 13F-HR |
| Q1 2022 | Mar 31, 2022 | May 13, 2022 | 25 | $275.4M | 13F-HR |
| Q4 2021 | Dec 31, 2021 | Feb 14, 2022 | 25 | $323.4M | 13F-HR |
| Q3 2021 | Sep 30, 2021 | Nov 12, 2021 | 28 | $335.7M | 13F-HR |
| Q2 2021 | Jun 30, 2021 | Aug 16, 2021 | 34 | $372.1M | 13F-HR |
| Q1 2021 | Mar 31, 2021 | May 14, 2021 | 36 | $324.6M | 13F-HR |
| Q4 2020 | Dec 31, 2020 | Feb 12, 2021 | 35 | $279.3M | 13F-HR |
| Q3 2020 | Sep 30, 2020 | Nov 13, 2020 | 39 | $197.2M | 13F-HR |
| Q2 2020 | Jun 30, 2020 | Aug 14, 2020 | 63 | $184.4M | 13F-HR |
Holdings from SEC EDGAR 13F-HR filings, updated quarterly ~45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. The performance line is a simulation of the disclosed long book, not an audited return.